Sam Chun Dang Pharm. Co., Ltd (KOSDAQ:000250)
South Korea
· Delayed Price · Currency is KRW 216,000
-7,500 (-3.36%)
At close: Dec 5, 2025
Sam Chun Dang Pharm. Revenue
Sam Chun Dang Pharm. had revenue of 58.02B KRW in the quarter ending September 30, 2025, with 10.77% growth. This brings the company's revenue in the last twelve months to 220.74B, up 6.01% year-over-year. In the year 2024, Sam Chun Dang Pharm. had annual revenue of 210.92B with 9.47% growth.
Revenue (ttm)
220.74B
Revenue Growth
+6.01%
P/S Ratio
22.76
Revenue / Employee
523.07M
Employees
419
Market Cap
5,023.70B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 210.92B | 18.26B | 9.47% |
| Dec 31, 2023 | 192.67B | 15.33B | 8.65% |
| Dec 31, 2022 | 177.34B | 10.06B | 6.01% |
| Dec 31, 2021 | 167.27B | 412.57M | 0.25% |
| Dec 31, 2020 | 166.86B | -19.74B | -10.58% |
| Dec 31, 2019 | Pro | Pro | Pro |
| Dec 31, 2018 | Pro | Pro | Pro |
| Dec 31, 2017 | Pro | Pro | Pro |
| Dec 31, 2016 | Pro | Pro | Pro |
| Dec 31, 2015 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Samsung Biologics | 5,504.84B |
| Celltrion | 3,895.99B |
| ALTEOGEN | 202.18B |
| ABL Bio | 88.44B |
| SK Biopharmaceuticals | 675.41B |
| Yuhan | 2,136.67B |
| LigaChem Biosciences | 159.27B |
| Peptron | 6.19B |